Literature DB >> 25460174

Time-dependent responses to provocative testing with flecainide in the diagnosis of Brugada syndrome.

David Calvo1, José M Rubín2, Diego Pérez2, Juan Gómez3, Juan Pablo Flórez2, Pablo Avanzas4, José Manuel García-Ruíz4, Jesús María de la Hera5, Julián Reguero4, Eliecer Coto3, César Morís4.   

Abstract

BACKGROUND: Time-dependent variability of electrocardiogram (ECG) in patients with Brugada syndrome could affect the interpretation of provocative testing.
OBJECTIVE: The aim of this study was to characterize ECG changes during and after flecainide infusion.
METHODS: We studied 59 consecutive patients. The ECG was continuously analyzed during the first 30 minutes of provocative testing, and a single ECG was recorded 60 minutes later. We analyzed CYP2D6 and CYP3A5 variants affecting flecainide metabolism and performed blinded measurements at lead II.
RESULTS: At baseline, ECG patterns were classified as follows: type II in 31 patients (53%), type III in 15 (25%), and normal ECG in 13 (22%). Because of induction of type I ECG, the percentage of responders progressively increased with longer recording time periods (6.8% in 10 minutes vs 11.9% in 20-30 minutes vs 18.6% in 90 minutes; P < .01). Four patients displayed a late response, which was evidenced 90 minutes after the initiation of provocative testing. QRS width differentially increased between responders and nonresponders (P < .01), with a maximum QRS width of 110 ms during the first 30 minutes being effective for identifying possible late responders (sensitivity 100%; specificity 85.6%; positive predictive value 88%; negative predictive value 100%). The incidence of CYP2D6 variants was lower in late responders than in early or delayed responders (0% vs 75% vs 100%; P = .04), while a homogeneous distribution of CYP3A5*3/*3 was observed in our population.
CONCLUSION: Response to flecainide exhibits time-dependent variability of ECG patterns and intervals. Longer periods of ECG recording increase the recognition probability of type I ECG.
Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brugada syndrome; Cytochrome P450; Electrocardiogram; Flecainide; Provocative testing

Mesh:

Substances:

Year:  2014        PMID: 25460174     DOI: 10.1016/j.hrthm.2014.10.036

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  5 in total

Review 1.  Brugada syndrome: clinical and genetic findings.

Authors:  Georgia Sarquella-Brugada; Oscar Campuzano; Elena Arbelo; Josep Brugada; Ramon Brugada
Journal:  Genet Med       Date:  2015-04-23       Impact factor: 8.822

2.  How often is patent foramen ovale an innocent bystander?

Authors:  Francesco Versaci; Giampiero Vizzari; Domenico Sergi; Giuseppe Andò; Antonio Trivisonno; Francesco Romeo
Journal:  Clin Case Rep       Date:  2017-10-26

3.  Analysis of the High-Frequency Content in Human QRS Complexes by the Continuous Wavelet Transform: An Automatized Analysis for the Prediction of Sudden Cardiac Death.

Authors:  Daniel García Iglesias; Nieves Roqueñi Gutiérrez; Francisco Javier De Cos; David Calvo
Journal:  Sensors (Basel)       Date:  2018-02-12       Impact factor: 3.576

4.  Spectral Analysis of the QT Interval Increases the Prediction Accuracy of Clinical Variables in Brugada Syndrome.

Authors:  Daniel García-Iglesias; Francisco Javier de Cos; Francisco Javier Romero; Srujana Polana; José Manuel Rubín; Diego Pérez; Julián Reguero; Jesús María de la Hera; Pablo Avanzas; Juan Gómez; Eliecer Coto; César Morís; David Calvo
Journal:  J Clin Med       Date:  2019-10-04       Impact factor: 4.241

Review 5.  Risk stratification of sudden cardiac death in Brugada syndrome: an updated review of literature.

Authors:  Charmake Darar; El-Azrak Mohammed; Boutaybi Mohammed; El Ouafi Noha; Bazid Zakaria
Journal:  Egypt Heart J       Date:  2022-04-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.